-DOCSTART- -X- O
In -X- _ O
the -X- _ O
last -X- _ O
decade -X- _ O
, -X- _ O
the -X- _ O
search -X- _ O
for -X- _ O
new -X- _ O
vaccines -X- _ O
against -X- _ O
canine -X- _ O
visceral -X- _ O
leishmaniasis -X- _ O
has -X- _ O
intensified. -X- _ O
However -X- _ O
, -X- _ O
the -X- _ O
pattern -X- _ O
related -X- _ O
to -X- _ O
immune -X- _ O
protection -X- _ O
during -X- _ O
long -X- _ O
periods -X- _ O
after -X- _ O
experimental -X- _ O
infection -X- _ O
in -X- _ O
vaccine -X- _ O
trials -X- _ O
is -X- _ O
still -X- _ O
not -X- _ O
fully -X- _ O
understood. -X- _ O
Herein -X- _ O
, -X- _ O
we -X- _ O
investigated -X- _ O
the -X- _ O
immunogenicity -X- _ O
and -X- _ O
parasitological -X- _ O
levels -X- _ O
after -X- _ O
intradermal -X- _ B-Intervention
challenge -X- _ I-Intervention
with -X- _ I-Intervention
Leishmania -X- _ I-Intervention
infantum -X- _ I-Intervention
plus -X- _ I-Intervention
salivary -X- _ I-Intervention
gland -X- _ I-Intervention
extract -X- _ O
in -X- _ O
dogs -X- _ B-Patient
immunized -X- _ I-Patient
with -X- _ I-Patient
a -X- _ I-Patient
vaccine -X- _ I-Patient
composed -X- _ I-Patient
of -X- _ I-Patient
L. -X- _ I-Patient
braziliensis -X- _ I-Patient
antigens -X- _ I-Patient
plus -X- _ I-Patient
saponin -X- _ I-Patient
as -X- _ I-Patient
an -X- _ I-Patient
adjuvant -X- _ I-Patient
( -X- _ I-Patient
LBSap -X- _ I-Patient
vaccine -X- _ I-Patient
) -X- _ I-Patient
. -X- _ O
The -X- _ O
LBSap -X- _ B-Outcome
vaccine -X- _ I-Outcome
elicited -X- _ I-Outcome
higher -X- _ I-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
total -X- _ I-Outcome
anti-Leishmania -X- _ I-Outcome
IgG -X- _ I-Outcome
as -X- _ I-Outcome
well -X- _ I-Outcome
as -X- _ I-Outcome
both -X- _ I-Outcome
IgG1 -X- _ I-Outcome
and -X- _ I-Outcome
IgG2. -X- _ I-Outcome
Furthermore -X- _ I-Outcome
, -X- _ I-Outcome
dogs -X- _ I-Outcome
vaccinated -X- _ I-Outcome
had -X- _ I-Outcome
increased -X- _ I-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
lymphocytes -X- _ I-Outcome
, -X- _ I-Outcome
particularly -X- _ I-Outcome
circulating -X- _ I-Outcome
B -X- _ I-Outcome
cells -X- _ I-Outcome
( -X- _ I-Outcome
CD21 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
both -X- _ I-Outcome
CD4 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
CD8 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
T -X- _ I-Outcome
lymphocytes. -X- _ I-Outcome
LBSap -X- _ I-Outcome
also -X- _ I-Outcome
elicited -X- _ I-Outcome
an -X- _ I-Outcome
intense -X- _ I-Outcome
in -X- _ I-Outcome
vitro -X- _ I-Outcome
cell -X- _ I-Outcome
proliferation -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
higher -X- _ I-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
CD4 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
T -X- _ I-Outcome
lymphocytes -X- _ I-Outcome
specific -X- _ I-Outcome
for -X- _ I-Outcome
vaccine -X- _ I-Outcome
soluble -X- _ I-Outcome
antigen -X- _ I-Outcome
and -X- _ I-Outcome
soluble -X- _ I-Outcome
lysate -X- _ I-Outcome
of -X- _ I-Outcome
L. -X- _ I-Outcome
infantum -X- _ I-Outcome
antigen -X- _ I-Outcome
even -X- _ I-Outcome
885 -X- _ I-Outcome
days -X- _ I-Outcome
after -X- _ I-Outcome
experimental -X- _ I-Outcome
challenge. -X- _ I-Outcome
Furthermore -X- _ I-Outcome
, -X- _ I-Outcome
LBSap -X- _ I-Outcome
vaccinated -X- _ I-Outcome
dogs -X- _ I-Outcome
presented -X- _ I-Outcome
high -X- _ I-Outcome
IFN-γ -X- _ I-Outcome
and -X- _ I-Outcome
low -X- _ I-Outcome
IL-10 -X- _ I-Outcome
and -X- _ I-Outcome
TGF-β1 -X- _ I-Outcome
expression -X- _ I-Outcome
in -X- _ I-Outcome
spleen -X- _ I-Outcome
with -X- _ I-Outcome
significant -X- _ I-Outcome
reduction -X- _ I-Outcome
of -X- _ I-Outcome
parasite -X- _ I-Outcome
load -X- _ I-Outcome
in -X- _ I-Outcome
this -X- _ I-Outcome
tissue. -X- _ I-Outcome
Overall -X- _ O
, -X- _ O
our -X- _ O
results -X- _ B-Outcome
validate -X- _ I-Outcome
the -X- _ I-Outcome
potential -X- _ I-Outcome
of -X- _ I-Outcome
LBSap -X- _ I-Outcome
vaccine -X- _ I-Outcome
to -X- _ I-Outcome
protect -X- _ I-Outcome
against -X- _ I-Outcome
L. -X- _ I-Outcome
infantum -X- _ I-Outcome
experimental -X- _ I-Outcome
infection -X- _ I-Outcome
and -X- _ I-Outcome
strongly -X- _ I-Outcome
support -X- _ I-Outcome
further -X- _ I-Outcome
evaluation -X- _ I-Outcome
of -X- _ I-Outcome
efficiency -X- _ I-Outcome
of -X- _ I-Outcome
LBSap -X- _ I-Outcome
against -X- _ I-Outcome
CVL -X- _ I-Outcome
in -X- _ I-Outcome
natural -X- _ I-Outcome
infection -X- _ I-Outcome
conditions -X- _ O
. -X- _ O

